Anti-diabetic Generics Portfolio
Type 2 Diabetes
Filed/ApprovedCommercial/Under Review
Key Facts
Indication
Type 2 Diabetes
Phase
Filed/Approved
Status
Commercial/Under Review
Company
About Alembic Pharmaceuticals
Alembic Pharmaceuticals is a vertically integrated, publicly listed Indian pharmaceutical company with a century-long legacy. It operates through two main segments: Generics and Branded Generics, with a robust manufacturing infrastructure and a growing international footprint, particularly in the US market. The company is strategically focused on complex generics, biosimilars, and specialty products to drive future growth, supported by significant R&D investments.
View full company profileTherapeutic Areas
Other Type 2 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| Tirzepatide (Mounjaro) | Eli Lilly | Approved |
| Orforglipron | Eli Lilly | Phase 3 |
| Trulicity (dulaglutide) | Eli Lilly | Approved |
| Forxiga | AstraZeneca | Approved |
| siRNA GalXC-GYS2 | Novo Nordisk | Phase 1 |
| Amylin/semaglutide combination | Novo Nordisk | Phase 3 |
| Lipaglyn | Zydus Lifesciences | Approved |
| LBS-009 | Belite Bio | Preclinical |
| Jentadueto (Linagliptin/Metformin) | Yuhan | Approved |
| Nesina (Alogliptin) | Yuhan | Approved |
| Metformin & Combinations | Ipca Laboratories | Commercial |
| GSBR-1290 | Structure Therapeutics | Phase 2 |